Concurrent Chagas' disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

The occurrence of mixed infections of Trypanosoma cruzi and Leishmania spp. is becoming a common feature in Central and South America due to overlapping endemic areas. Unfortunately, the possibilities for treating flagellated kinetoplastid infections are still very limited and most of the available...

Full description

Saved in:
Bibliographic Details
Published inTherapeutics and clinical risk management Vol. 4; no. 3; pp. 659 - 663
Main Authors Paniz-Mondolfi, Alberto E, Pérez-Alvarez, Alexandra M, Reyes-Jaimes, Oscar, Socorro, Gustavo, Zerpa, Olga, Slova, Denisa, Concepción, Juan L
Format Journal Article
LanguageEnglish
Published New Zealand Taylor & Francis Ltd 01.06.2008
Dove Press
Dove Medical Press
Subjects
amiodarone
Case Report
Case reports
Chagas disease
chemotherapy
leishmaniasis
Parasitic diseases
Protozoa
amiodarone
leishmaniasis
chemotherapy
Chagas’ disease
Online AccessGet full text

Cover

More Information
Summary:The occurrence of mixed infections of Trypanosoma cruzi and Leishmania spp. is becoming a common feature in Central and South America due to overlapping endemic areas. Unfortunately, the possibilities for treating flagellated kinetoplastid infections are still very limited and most of the available drugs exhibit severe side effects. Although the development of new drugs for Leishmania has markedly improved in the last years, the tendency is still to employ antimonial compounds. On the other hand, treatment for Chagas' disease is only available for the acute phase with no effective therapeutical options for chronic stage disease. The following case report substantiates the recently discovered effect of amiodarone as a nonconventional antiparasitic drug, particularly against Leishmania, breaching a new perspective in the therapeutic management of these important infectious parasitic diseases.
ISSN:1176-6336
1178-203X
1178-203X
DOI:10.2147/TCRM.S2801